Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Fudd who wrote (34312)	4/24/2007 8:43:53 AM
From: Jack Russell	Respond to of 48461

PVCT NEWS... Provectus Pharmaceuticals, Inc. Completes Dosing of Patients in Phase 1 Melanoma Study Tuesday April 24, 8:30 am ET Announces Successful Attainment of the Study Objectives KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT - News) has successfully completed dosing in the final patient enrolled in its Phase 1 study of Provecta(TM) for use on Stage III/IV metastatic melanoma. Provecta is the company's proprietary drug being tested for treatment of metastatic melanoma, breast cancer and liver cancer. Craig Dees, Ph.D., Chief Executive Officer of Provectus stated "We are happy to announce that the endpoints of this study of the safety and preliminary effectiveness of Provecta appear to have been met. While it will be several months before final follow-up is completed for the last patient, Provecta was generally well tolerated by all 20 patients with minimal side effects. Furthermore, interim analysis of final data from the first 11 patients indicates that the rate of response for a single injection of their tumors with Provecta was at least several times greater than that typically achieved using the standard drugs administered to patients in the U.S. Even though the drug is administered by direct injection into an individual tumor, a number of patients displayed evidence that non-injected tumors responded as well. The presence of this 'bystander effect' is significant because it demonstrates that Provecta likely triggers systemic anti-tumor activity. Demonstration of systemic activity is critical in improving patient outcomes." Current drug therapies for metastatic melanoma include systemic use of interferon-alpha and the chemotherapeutic agent DTIC. Both require repeat dosing over a period of weeks to months or longer, have significant side effects, and have exhibited a response rate of less than 20% in clinical trials. Dees noted, "PV-10 differs dramatically from these conventional therapies in several key ways. First, PV-10 is injected only into the tumor itself, causing cell death and the release of large amounts of tumor antigen. Second, the resulting destruction of the injected tumors appears to elicit an anti-tumor immune response, the so called 'bystander effect,' that can lead to spontaneous regression of untreated tumors. For patients with metastatic disease, this may mean improved outcome in both their treated tumors and in metastases elsewhere that cannot be easily treated, or have yet to be detected." "With this critical study essentially complete, we are making final preparations to begin the next round of testing intended to definitively demonstrate efficacy of Provecta. We expect to begin this study within several months, treating up to 80 Stage III/IV melanoma patients at seven or more sites in Australia and the U.S. We will follow their response for 12 months to allow us to gauge both local response in their treated tumors and their longer-term outcome." The company expects to release detailed results from the Phase 1 study throughout the year as final follow-up is completed for all subjects. About Provectus Pharmaceuticals, Inc. Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus takes a macroscopic, or "big picture", approach by applying small-molecule drugs that target diseased tissue, allowing the therapy to selectively attack broad classes of disease. This opposes current industry trends that take a molecular (microscopic) approach. Provectus is currently conducting clinical trials of their proprietary drugs Provecta(TM) (PV-10) as a therapy for melanoma and breast cancer, as well as Xantryl(TM), a topical treatment for severe psoriasis and eczema. The company expects to commence Phase 2 clinical testing of Provecta for melanoma in the near future. Further, use of Provecta for melanoma has received orphan drug designation from the FDA. Initial Phase 1 clinical trial objectives for Provecta for breast cancer were completed in April 2006, but the trial was extended to more properly determine optimal dosing. The extended Phase 1 trial is also nearing completion and the company anticipates reporting those results in the near future. Additionally, the company is about to begin Phase 2 of clinical testing for Xantryl for psoriasis. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of medical devices and biotechnology. For additional information about Provectus please visit the company's website at www.pvct.com or contact The Investor Relations Group via the information provided below. FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof. Contact: Provectus Pharmaceuticals, Inc. Peter R. Culpepper, CFO, 865-769-4011 or The Investor Relations Group Investor Relations: Joseph Kessler or Media: Janet Vasquez 212-825-3210